Every clinical trial result begins with a sample.
No matter how sophisticated a testing platform becomes, the quality of the resulting data depends on the quality of the specimen entering the laboratory.
As clinical trials become increasingly global and biomarker-driven, maintaining specimen integrity has become more important than ever.
According to Eurofins' scientific leadership, when a sample is lost or compromised, the scientific data is often gone forever. That reality makes chain-of-custody management a foundational element of clinical research.
Potential risks include:
Collection errors
Temperature excursions
Transportation delays
Documentation discrepancies
Storage failures
Each represents a threat to data quality and study success.
Innovations such as electronic requisitioning and integrated laboratory information systems provide opportunities to strengthen specimen oversight.
The whitepaper notes that validated studies of Eurofins Central Laboratory's EzRF™ platform demonstrated an 80% reduction in query generation compared with paper-based requisitioning processes.
Reducing errors upstream can improve efficiency throughout the clinical trial.
In an era of precision medicine, sample quality remains inseparable from data quality.
Organizations that prioritize specimen integrity create stronger foundations for scientific confidence and regulatory success.